Receptos, Inc. (Receptos) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics in immune disorders. Its product candidates span three disease areas. It is developing its lead asset, ozanimod (formerly RPC1063), as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD), which consists of Ulcerative Colitis (UC) and Crohn's Disease (CD). It is developing its second asset, RPC4046, for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis (EoE), for which it has been granted Orphan drug designation. Its research efforts include a preclinical program developing oral, small molecule, positive allosteric modulators (PAMs) of the glucagon-like peptide-1 receptor (GLP-1R) for the treatment of Type 2 Diabetes.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:RCPT
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $226.05
- 200 Day Moving Avg: $174.22
- 52 Week Range: $46.94 - $232.02
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -28.25
- P/E Growth: 0.00
- Average Volume: 1.16 million shs.
Frequently Asked Questions for Receptos (NASDAQ:RCPT)
What is Receptos' stock symbol?
Receptos trades on the NASDAQ under the ticker symbol "RCPT."
How were Receptos' earnings last quarter?
Receptos Inc (NASDAQ:RCPT) released its earnings results on Tuesday, May, 5th. The company reported ($1.29) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.09) by $0.20. View Receptos' Earnings History.
Who are some of Receptos' key competitors?
Some companies that are related to Receptos include Amgen (AMGN), Celgene (CELG), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Illumina (ILMN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), BIO-TECHNE Corp (TECH) and Kite Pharma (KITE).
How do I buy Receptos stock?
Shares of Receptos can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Receptos stock cost?
One share of Receptos stock can currently be purchased for approximately $231.96.
Earnings History for Receptos (NASDAQ:RCPT)Earnings History by Quarter for Receptos (NASDAQ:RCPT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/4/2014||Q314||($0.96)||($1.19)||$1.00 million||$3.45 million||View||N/A|
|8/12/2014||Q214||($0.85)||($1.04)||$1.28 million||$1.10 million||View||N/A|
|5/12/2014||Q114||($0.84)||($1.01)||$0.49 million||$1.40 million||View||N/A|
|3/5/2014||($0.86)||($0.86)||$1.16 million||$0.77 million||View||N/A|
Earnings Estimates for Receptos (NASDAQ:RCPT)
Current Year EPS Consensus Estimate: $-7.14 EPS
Next Year EPS Consensus Estimate: $-8.21 EPS
Dividend History for Receptos (NASDAQ:RCPT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Receptos (NASDAQ:RCPT)Insider Trades by Quarter for Receptos (NASDAQ:RCPT)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/16/2015||S. Edward Torres||Director||Sell||220,000||$178.99||$39,377,800.00|| |
|2/23/2015||S. Edward Torres||Director||Sell||47,906||$128.20||$6,141,549.20|| |
|11/11/2014||Faheem Hasnain||CEO||Sell||200,000||$109.47||$21,894,000.00|| |
|11/11/2014||Sheila Gujrathi||Insider||Sell||30,000||$108.99||$3,269,700.00|| |
|11/10/2014||Chrysa Mineo||SVP||Sell||30,000||$109.73||$3,291,900.00|| |
|11/10/2014||Faheem Hasnain||CEO||Sell||136,795||$109.69||$15,005,043.55|| |
|11/10/2014||Marcus F Boehm||CTO||Sell||40,454||$109.91||$4,446,299.14|| |
|9/23/2014||S. Edward Torres||Director||Sell||100,000||$61.36||$6,136,000.00|| |
|9/22/2014||S. Edward Torres||Director||Sell||14,318||$63.08||$903,179.44|| |
|9/22/2014||Sheila Gujrathi||Insider||Sell||30,000||$61.45||$1,843,500.00|| |
|9/19/2014||S. Edward Torres||Director||Sell||169,570||$62.55||$10,606,603.50|| |
|9/18/2014||S. Edward Torres||Director||Sell||91,513||$62.77||$5,744,271.01|| |
|9/17/2014||David A Hinkle||CAO||Sell||2,000||$64.82||$129,640.00|| |
|9/17/2014||S. Edward Torres||Director||Sell||38,917||$63.67||$2,477,845.39|| |
|9/16/2014||Graham K Cooper||CFO||Sell||50,000||$61.30||$3,065,000.00|| |
|9/2/2014||David A Hinkle||CAO||Sell||2,000||$52.80||$105,600.00|| |
|8/13/2014||David A Hinkle||CAO||Sell||3,000||$42.69||$128,070.00|| |
|8/13/2014||S. Edward Torres||Director||Sell||200,000||$43.24||$8,648,000.00|| |
|5/29/2014||Kristina Burow||Director||Sell||153,698||$29.74||$4,570,978.52|| |
|5/21/2014||S. Edward Torres||Director||Sell||424,068||$25.26||$10,711,957.68|| |
|5/15/2014||S. Edward Torres||Director||Sell||90,075||$27.37||$2,465,352.75|| |
|5/14/2014||Kristina Burow||Director||Sell||45,381||$29.66||$1,346,000.46|| |
|1/3/2014||William Rastetter||Director||Sell||37,359||$30.85||$1,152,525.15|| |
|1/2/2014||William Rastetter||Director||Sell||27,581||$30.29||$835,428.49|| |
|12/6/2013||Amir Nashat||Director||Sell||170,000||$26.70||$4,539,000.00|| |
|12/5/2013||William Rastetter||Director||Sell||500,000||$27.63||$13,815,000.00|| |
|11/18/2013||Ventures Fund 2007 Flagship||major shareholder||Sell||230,787||$24.75||$5,711,978.25|| |
|11/15/2013||Amir Nashat||Director||Sell||169,315||$24.96||$4,226,102.40|| |
|5/14/2013||Amir Nashat||Director||Buy||151,343||$14.00||$2,118,802.00|| |
|5/14/2013||Ventures Fund 2007 L Flagship||Major Shareholder||Buy||107,142||$14.00||$1,499,988.00|| |
Headline Trends for Receptos (NASDAQ:RCPT)
Latest Headlines for Receptos (NASDAQ:RCPT)
Receptos (RCPT) Chart for Sunday, May, 28, 2017